Pharmacy benefit manager CVS Caremark drops Zepbound coverage, estimating 10-15% savings while Eli Lilly offers self-pay ...

Do those on Zepbound have to switch to Wegovy after Caremark drops Zepbound from preferred coverage? What options are there?

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.

The first study to put two GLP-1 weight loss drugs head-to-head found Zepbound helped people lose more weight than Wegovy.

Reduced monthly costs for uninsured patients still amount to around $500. That can put the drugs out of reach for many.

Zepbound is a once-weekly injectable weight loss medication that contains tirzepatide as its active ingredient. In 2023, it was approved for use for chronic weight management in adults living with ...

Health insurance companies, including CVS Caremark, are altering coverage for GLP-1 weight loss medications like Zepbound, ...

CVS Caremark has removed coverage of Zepbound, a GLP-1 weight-loss drug, citing pricing concerns and shifting payer dynamics ...

This change is happening because there’s another covered medication that’s safe and effective for your condition and may cost ...

Three people share the hoops they've jumped through, financial strain they've endured and risks they've taken on in order to ...

For reference, Novo Nordisk also offers a highly successful weight loss drug, Wegovy, a GLP-1 receptor agonist.